Oklahoma Heart Institute becomes first in the world to use Edwards PASCAL Precision system

Oklahoma Heart Institute (OHI), in partnership with the Oklahoma Heart Research & Education Foundation and Edwards Lifesciences, was the first center in the world to use the new Edwards PASCAL Precision system for treatment of severe mitral valve regurgitation (leaky heart valve) as part of the CLASP IID/IIF Pivotal Trial on May 25, 2021.

This research trial is a prospective, multicenter, randomized, controlled pivotal trial to evaluate the safety and effectiveness of transcatheter mitral valve repair with the Edwards PASCAL Transcatheter Valve Repair System compared to the Abbott MitraClip in patients with degenerative mitral regurgitation (DMR) who have been determined to be at prohibitive risk for open-heart mitral valve surgery by the heart team and in patients with functional mitral regurgitation (FMR) on guideline-directed medical therapy (GDMT).

OHI is pleased to be the first center in the world to utilize the next-generation PASCAL Precision system. OHI is one of 65 major U.S. cardiac centers participating in the CLASP IID/IIF trial. Patients who are enrolled in this trial may be candidates for minimally-invasive, non-surgical transcatheter mitral valve repair to treat their leaky mitral valve with the Edwards PASCAL device.

OHI continues to be the leader in innovation for the treatment of heart disease in Oklahoma and the region. For more information or to make an appointment, please call 918-592-0999.